Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.

In the phase 1b portion of the MELT-MM trial, elranatamab plus mezigdomide produced a 100% overall response rate in relapsed/refractory multiple myeloma.

A pooled analysis of the AMY2009 and AMY3001 trials showed daratumumab plus VCd yielded hematologic complete responses in cardiac-involved AL amyloidosis.

David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.

Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.

Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.

In the LINKER-SMM1 trial, single-agent linvoseltamab produced a 100% overall response rate among evaluable patients with high-risk smoldering multiple myeloma.

Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.